BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22649104)

  • 1. How I treat prolymphocytic leukemia.
    Dearden C
    Blood; 2012 Jul; 120(3):538-51. PubMed ID: 22649104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B- and T-cell prolymphocytic leukemia: antibody approaches.
    Dearden C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():645-51. PubMed ID: 23233647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolymphocytic leukemias.
    Krishnan B; Matutes E; Dearden C
    Semin Oncol; 2006 Apr; 33(2):257-63. PubMed ID: 16616073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
    Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
    Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B and T cell prolymphocytic leukaemia.
    Cross M; Dearden C
    Best Pract Res Clin Haematol; 2019 Sep; 32(3):217-228. PubMed ID: 31585622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolymphocytic Leukemia: New Insights in Diagnosis and in Treatment.
    Collignon A; Wanquet A; Maitre E; Cornet E; Troussard X; Aurran-Schleinitz T
    Curr Oncol Rep; 2017 Apr; 19(4):29. PubMed ID: 28324286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of prolymphocytic leukemia.
    Dearden C
    Hematology Am Soc Hematol Educ Program; 2015; 2015():361-7. PubMed ID: 26637744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T-cell prolymphocytic leukemia.
    Khot A; Dearden C
    Expert Rev Anticancer Ther; 2009 Mar; 9(3):365-71. PubMed ID: 19275513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current treatment options in prolymphocytic leukemia.
    Robak T; Robak P
    Med Sci Monit; 2007 Apr; 13(4):RA69-80. PubMed ID: 17392661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of donor chimerism in remission after allogeneic stem cell transplantation of T-prolymphocytic leukemia patients following alemtuzumab induction therapy.
    Szuszies CJ; Hasenkamp J; Jung W; Koch R; Trümper L; Wulf GG
    Int J Hematol; 2014 Nov; 100(5):425-8. PubMed ID: 25258193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete response to alemtuzumab in a patient with B prolymphocytic leukemia.
    Chaar BT; Petruska PJ
    Am J Hematol; 2007 May; 82(5):417. PubMed ID: 17160995
    [No Abstract]   [Full Text] [Related]  

  • 12. Alemtuzumab in peripheral T-cell malignancies.
    Dearden C
    Cancer Biother Radiopharm; 2004 Aug; 19(4):391-8. PubMed ID: 15453953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolymphocytic leukemia.
    Absi A; Hsi E; Kalaycio M
    Curr Treat Options Oncol; 2005 May; 6(3):197-208. PubMed ID: 15869731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell prolymphocytic leukemia.
    Dearden CE
    Med Oncol; 2006; 23(1):17-22. PubMed ID: 16645226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
    McCune SL; Gockerman JP; Moore JO; Decastro CM; Bass AJ; Chao NJ; Long GD; Vredenburgh JJ; Gasparetto C; Adams D; Payne N; Rizzieri DA
    Leuk Lymphoma; 2002 May; 43(5):1007-11. PubMed ID: 12148879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy.
    Hu Z; Li S; Medeiros LJ; Sun T
    Hum Pathol; 2017 Jul; 65():175-179. PubMed ID: 28232160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
    Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
    Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies in the treatment of chronic lymphoid leukemias.
    Robak T
    Leuk Lymphoma; 2004 Feb; 45(2):205-19. PubMed ID: 15101704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
    Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T-cell prolymphocytic leukemia.
    Dearden CE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S239-43. PubMed ID: 19778847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.